Incretin Atlas › Trials › HRS-7535 phase 2 (add-on to metformin + SGLT2i)
HRS-7535 phase 2 (add-on to metformin + SGLT2i)
HRS-7535 · t2d
Design
- Molecule(s)
- HRS-7535
- Population
- t2d
- Phase
- 2
- Participants
- 53
- Duration
- 16 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRS-7535 30 mg | t2d china | 16 | 51 | — | — | −1.5 vs −0.4 | 0.0 vs 2.0 | — | 15.7 vs 2.0 | 13.7 vs 2.0 | 7.8 vs 0.0 | — | verified |
| HRS-7535 60 mg | t2d china | 16 | 53 | — | —−2.4 % vs −0.7 % estimand not specified | −1.8 vs −0.4 | 0.0 vs 2.0 | — | 21.2 vs 2.0 | 19.2 vs 2.0 | 3.8 vs 0.0 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- HRS-7535 30 mg: HbA1c from the abstract (estimand not named; ESM: primary estimand uses a hypothetical strategy). Safety from ESM Tables 5–6. Weight for 30 mg not reported; main text not available to us.
- HRS-7535 60 mg: HbA1c from the abstract (estimand not named; ESM: primary estimand uses a hypothetical strategy). Safety from ESM Tables 5–6. Weight for 30 mg not reported; main text not available to us.
Verbatim quotes from the source (11)
- HRS-7535 30 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
TEAEs leading to treatment discontinuation 1 (2.0) 0 0
- HRS-7535 30 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Nausea 1 (2.0) 8 (15.7) 11 (21.2)
- HRS-7535 30 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
- HRS-7535 30 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
Serious adverse events 0 4 (7.8) 2 (3.8)
- HRS-7535 30 mg · hba1c · Abstract RESULTS
placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo
- HRS-7535 60 mg · weight_unsp · Abstract RESULTS
(6.5%) were 35.3%, 37.7% and 3.9%, respectively. Body weight loss was -2.4% in the HRS-7535 60 mg group vs -0.7% in the placebo group. Most treatment-emergent
- HRS-7535 60 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
TEAEs leading to treatment discontinuation 1 (2.0) 0 0
- HRS-7535 60 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Nausea 1 (2.0) 8 (15.7) 11 (21.2)
- HRS-7535 60 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
- HRS-7535 60 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
Serious adverse events 0 4 (7.8) 2 (3.8)
- HRS-7535 60 mg · hba1c · Abstract RESULTS
placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HRS-7535 phase 2 (add-on to metformin + SGLT2i). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-7535-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.